Émilie Lemasle
A5033731496- Acute Myeloid Leukemia Research
- PARP inhibition in cancer therapy
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Nutrition and Health in Aging
- Nuclear Structure and Function
- Blood disorders and treatments
- Multiple Myeloma Research and Treatments
- Metal complexes synthesis and properties
- Protein Degradation and Inhibitors
- Ferrocene Chemistry and Applications
- Hematological disorders and diagnostics
- Digital Imaging for Blood Diseases
- Brain Tumor Detection and Classification
- Cancer Immunotherapy and Biomarkers
- Cancer-related cognitive impairment studies
Centre Henri Becquerel
2010-2025
Laboratoire National Henri Becquerel
2012-2023
Centre Virchow-Villermé
2015-2023
Hôpital Lyon Sud
2017
Institut Gustave Roussy
2017
Assistance Publique – Hôpitaux de Paris
2017
Acute Leukemia French Association
2017
Université Paris Cité
2017
Saint Louis University Hospital
2017
Centre Hospitalier Universitaire de Rouen
2015
Purpose This study assessed the prognostic impact of postinduction NPM1-mutated ( NPM1m) minimal residual disease (MRD) in young adult patients (age, 18 to 60 years) with acute myeloid leukemia, and addressed question whether NPM1m MRD may be used as a predictive factor allogeneic stem cell transplantation (ASCT) benefit. Patients Methods Among 229 who were treated Acute Leukemia French Association 0702 (ALFA-0702) trial, evaluation was available 152 first remission. nonfavorable AML...
Abstract In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or (median age, 68 years) were prospectively enrolled in the Acute Leukemia French Association (ALFA)-1200 trial between 2012 2016, 471 patient samples submitted multigene analysis. Mutations any 8 genes frequently altered myelodysplastic syndromes (MDS), including ASXL1, SRSF2, STAG2, BCOR, U2AF1, EZH2, SF3B1, ZRSR2,...
Despite progress in the understanding of leukemia pathophysiology, treatment acute myeloid (AML) remains challenging. In patients with refractory or relapsed (R/R) AML, prognosis is still poor and this group targeted for new drug development. We reviewed outcome 47 patients, R/R AML after at least one course intensive chemotherapy, treated 5-azacytidine three different French institutions. The overall response rate was 38% including complete remission 21%, partial 11%, hematological...
PPM1D, a central regulator of the DNA damage response, is commonly mutated in therapy-related clonal hematopoiesis (CH), acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). PPM1D mutations have been shown to expand under selective pressure DNA-damaging chemotherapy. However, whether promote development hematologic malignancies remains unclear. We characterized clinical genomic profiles 112 PPM1D-mutated patients across spectrum disorders using combination bulk single-cell...
Introduction: Early detection of fever is crucial in neutropenic patients. Lack precision body temperature measurement can occur with peripheral site measurements. Furthermore, intermittent monitoring may result a delay detection. Methods: We conducted prospective study hematological intensive care unit (HICU) patients receiving autologous stem cell transplant or chemotherapy order to compare tympanic and enteral measured by an ingested electronic pill (BodyCap ®, France). Results:...
Purpose To evaluate the efficacy and safety of a clofarabine-based combination (CLARA) versus conventional high-dose cytarabine (HDAC) as postremission chemotherapy in younger patients with acute myeloid leukemia (AML). Patients Methods age 18 to 59 years old intermediate- or unfavorable-risk AML first remission no identified donor for allogeneic stem-cell transplantation (SCT) were eligible. Two hundred twenty-one randomly assigned receive three CLARA HDAC consolidation cycles. The primary...
To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi).In a French cancer center, we identified described profiles 13 t-MN diagnosed among 37 patients with ovarian referred to hematology consultation for cytopenia under PARPi. Next, these post-PARPi post according PARPi exposure. Finally, 69 in national cohort.From 2016 2021, cumulative incidence was 3.5% (13/373) treated At time hematologic consultation, had longer...
Both peripherally inserted central catheters (PICCs) and implanted port (PORTs) are commonly used for the delivery of immunochemotherapy. We compared safety two types devices in a homogeneous monocentric population diffuse large B-cell lymphoma (DLBCL) patients who were treated with first-line immunochemotherapy by evaluating numbers catheter-related venous thromboses (VTs) infections that occurred six months after implantation according to type device.Using propensity score, adjusted...
Abstract Whether the LSC17 gene expression can improve risk stratification in context of next generation sequencing–based and measurable residual disease (MRD) patients with intensively treated AML has not been explored. We analyzed 504 adult prospectively ALFA-0702 trial. RUNX1 or TP53 mutations were associated higher LSC1 scores while CEBPA NPM1 lower scores. Patients high had a rate complete response (CR) multivariable analysis (odds ratio, 0.41; P = .0007), accounting for European...
Patients with NPM1-mutated AML M5 who develop spontaneous remission (SR) after antibiotic therapy at diagnosis seem to form a favorable prognosis and chemo sensitive subtype. We report three cases of patients the same genotype that experienced transient SR are now leukemia free standard treatment.
Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas
Acute myeloid leukemia (AML) encompasses heterogeneous entities with dismal outcomes. Intermediate and unfavorable-risk AML represent the most difficult-to-treat entities. We recently reported benefit of clofarabine-based consolidation (CLARA) regimen compared to standard high-dose cytarabine (HDAC) in younger patients. Here, we aimed at assessing clinical significance single-nucleotide polymorphism (SNP)-array alterations their interactions chemotherapy regimens. A SNP-array was...
Key Clinical Message This case report highlights the potential of belinostat for treatment relapsed/refractory peripheral T‐cell lymphomas, which effective therapies are still scarce. Abstract Peripheral lymphomas have an aggressive disease course associated with poor outcomes. We a young patient highly pretreated nodal follicular helper lymphoma (angioimmunoblastic‐type [nTFHL‐AI]), who successfully received allogeneic stem cell transplantation following therapy. The complete hematologic...